A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma
Status:
Recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
This is a first in human, open-label, dose escalation and expansion Phase 1 study of
SIM1811-03 in adult patients with advanced solid tumors and cutaneous T-cell lymphoma.
SIM1811-03 is a first-in-class IgG1-based humanized anti-tumor necrosis factor type 2
receptor (TNFR2) monoclonal antibody for the treatment of malignant tumors.